Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Target Price of $5.46 According to Analysts

Key Points

• Analysts have a consensus “Hold” rating on Cellectis, with two sell, two hold, two buy and one strong-buy recommendation. The average 12-month price target is $5.46.
• Recent analyst views have become more cautious: Barclays downgraded the stock to “underweight” and cut its target to $1.30, while Wells Fargo lowered its target to $3.00; Baird also reduced its target to $8.00 but maintained an “outperform” rating.
• Cellectis shares opened at $0.98, near their one-year low of $0.88, while the company reported a quarterly loss of $0.22 per share—better than expected—but revenue of $6.9 million fell short of estimates.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) has received a consensus recommendation of "Hold" from the seven analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $5.46.

CLLS has been the topic of several research reports. Robert W. Baird dropped their target price on Cellectis from $10.00 to $8.00 and set an "outperform" rating on the stock in a research report on Tuesday, September 15th. Barclays cut shares of Cellectis from an "overweight" rating to an "underweight" rating and reduced their target price for the company from $9.00 to $1.30 in a report on Wednesday, September 16th. Citizens Jmp reissued a "market perform" rating on shares of Cellectis in a research report on Tuesday, September 15th. Weiss Ratings raised Cellectis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 2nd. Finally, Wells Fargo & Company cut their price target on Cellectis from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, September 15th.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC purchased a new position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,094 shares of the biotechnology company's stock, valued at approximately $32,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Stock Performance

Cellectis stock opened at $0.98 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The firm has a 50-day moving average of $2.10 and a 200-day moving average of $2.89. The firm has a market cap of $98.33 million, a P/E ratio of -1.51 and a beta of 3.00. Cellectis has a 1-year low of $0.88 and a 1-year high of $5.45.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The business had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

About Cellectis

Cellectis SA is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company's primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.